secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-277627
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea Q3 net loss $42.0M ($0.53/share); HCV Phase 3 C-BEYOND fully enrolled by end-2025; HEV program launched
--------------------------------------------------------------------------------

- Net loss of $42.0M ($0.53 diluted EPS) vs $31.2M ($0.37) in Q3 2024; R&D expenses rose to $38.3M.
- Cash, equivalents and marketable securities $329.3M at Sep 30, 2025, down from $454.7M at Dec 31, 2024.
- HCV Phase 3 C-BEYOND (US/Canada) enrollment on track for completion by end 2025; topline mid-2026.
- New HEV development program with two lead candidates AT-587 and AT-2490; IND-enabling studies ongoing.
- Completed $25M stock repurchase program: 7,673,793 shares at avg $3.26; shares outstanding 78,126,796.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525277627/0001193125-25-277627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525277627/d47505d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-277627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer